Drug intelligence / Profile preview

AVTP40X

Development stage: Preclinical
Lead developer: Aventi Biotechnology
Modality: Recombinant Proteins and Enzymes

Overview

AVTP40X is a preclinical-stage therapeutic candidate being developed by Aventi Biotechnology. It is categorized as a myokine, a type of muscle-derived signaling protein that plays a role in inter-organ communication and metabolic regulation. The drug is currently being investigated for its potential anti-aging effects. Although the specific molecular target and mechanism of action have not been disclosed by the developer, myokine-based therapies are generally explored for their ability to counteract age-related physiological decline and improve systemic health.

Beyond the preview

Go deeper on AVTP40X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVTP40X.

Explore the full profile